Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/23/2012EP2454249A1 Compounds as hypoxia mimetics, and compositions, and uses thereof
05/23/2012EP2454248A1 Anti -influenza agents
05/23/2012EP2454243A2 Tetrazole derivatives
05/23/2012EP2454240A1 Glycine transporter inhibitors
05/23/2012EP2454239A1 Substituted triazole and imidazole derivatives as gamma secretase modulators
05/23/2012EP2454238A1 Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
05/23/2012EP2454237A1 3-0x0-2, 3, -dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition
05/23/2012EP2454236A1 3-oxo-2, 3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors
05/23/2012EP2454234A2 3-phenoxymethylpyrrolidine compounds
05/23/2012EP2454229A1 Amino acid derivatives for the treatment of neuropathic pain
05/23/2012EP2454228A2 Process for the preparation of o-desmethyl venlafaxine and intermediate for use therein
05/23/2012EP2453923A2 Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
05/23/2012EP2453922A1 Antibacterial oral composition
05/23/2012EP2453912A1 Process and composition for treatment of canine and human leishmaniasis
05/23/2012EP2453904A1 Thin film compositions and methods of synthesis and use therefor
05/23/2012EP2453903A2 Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes
05/23/2012EP2453902A1 Mixture of non-digestible oligosaccharides for stimulating the immune system
05/23/2012EP2453901A1 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
05/23/2012EP2453900A1 Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
05/23/2012EP2453899A1 Humic substances and therapeutic uses thereof
05/23/2012EP2453898A1 Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases
05/23/2012EP2453897A1 Combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative
05/23/2012EP2453896A2 Methods for treating schizophrenia
05/23/2012EP2453895A1 (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
05/23/2012EP2453894A1 Crystalline freebase forms of a biphenyl compound
05/23/2012EP2453893A1 Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers
05/23/2012EP2453892A1 Compounds and methods for the treatment of cancer
05/23/2012EP2453891A1 Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
05/23/2012EP2453890A1 Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
05/23/2012EP2453889A1 Use of proanthocyanidins for production of an antiadhesive preparation
05/23/2012EP2453888A1 Use of at least one omega-3 fatty acid and of at least one polyphenol for the endogenous synthesis of eicosapentanoic acid and docosahexanoic acid
05/23/2012EP2453887A1 Use of pro-inflammatory compounds for promoting bone formation
05/23/2012EP2453886A2 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
05/23/2012EP2453885A1 Exo-s-mecamylamine method, use, and compound for treatment
05/23/2012EP2453884A1 Method for inhibiting the maturation of dendritic cells
05/23/2012EP2453883A1 Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
05/23/2012EP2453882A1 Methods of increasing liver proliferation
05/23/2012EP2453880A1 Separating layers for pharmaceutical preparations to prevent interactions between medicinal drugs and pharmaceutical-technological adjuvants
05/23/2012EP2453879A2 Pellets formulation
05/23/2012EP2453878A1 Material and process for incorporation of low dosage active pharmaceutical ingredients and use thereof
05/23/2012EP2453872A2 Olopatadine nasal spray regimen for children
05/23/2012EP2453870A2 Injectable formulations containing asenapine and method of treatment using same
05/23/2012EP2453765A1 Beverage product with resveratrol
05/23/2012EP2453759A1 Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof
05/23/2012EP2453748A1 Treatment method
05/23/2012EP2453747A1 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
05/23/2012EP2453746A1 Tazarotene derivatives
05/23/2012EP2453743A1 N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen
05/23/2012EP2453742A1 Treating patients with intravenous ibuprofen
05/23/2012EP2310372B1 Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
05/23/2012EP2292230B1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
05/23/2012EP2292229B1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
05/23/2012EP2241569B1 Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses
05/23/2012EP2209373B1 N-substituted oxindoline derivatives as calcium channel blockers
05/23/2012EP2197842B1 2, 3-substituted indole derivatives for treating viral infections
05/23/2012EP2124946B1 The use of n-methyl pyridinium derivatives for hepatoprotection
05/23/2012EP2046797B1 Furo [3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors
05/23/2012EP2044099B1 Process for the preparation of s-fluoromethyl-6 ,9 -difluoro-11 -hydroxy-16 -methyl-17 -propionyloxy-3-oxo-androsta-1,4-diene-17 -carbothioate and intermediates
05/23/2012EP2036903B1 Potentiator of radiation therapy
05/23/2012EP2027096B1 Substituted arylimidaz0l0ne and triaz0l0ne as inhibitors of vasopressin receptors
05/23/2012EP2004161B1 Oral composition comprising dha and genistein for enhancing skin properties
05/23/2012EP2001469B1 Thiazolidinedione analogues
05/23/2012EP1949903B8 Selective a2a receptor antagonists for the treatment of auricular fibrillation
05/23/2012EP1932522B1 Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient
05/23/2012EP1838287B1 Process for preparing granulates comprising amoxicillin
05/23/2012EP1833986B1 Determinants of sensitivity to chemotherapeutic agents
05/23/2012EP1806151B1 Drug for external use and adhesive patch
05/23/2012EP1755555B1 Methods for preparing dry powder compositions of glycopyrrolate
05/23/2012EP1663283B1 Glutamine for use in treating injury
05/23/2012EP1660057B1 Combination therapy for the treatment of ocular neovascular disorders
05/23/2012EP1474408B1 N-phenyl-2-pyrimidine-amine derivatives
05/23/2012EP1443900B1 Lipid carrier compositions with enhanced blood stability
05/23/2012EP1346059B1 Photochemical internalization for delivery of molecules into the cytosol
05/23/2012EP1325014B1 Gamma-hydroxybutyrate compositions containing carbohydrate carriers
05/23/2012CN1997645B Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors
05/23/2012CN1964733B Novel use of peptide compounds for treating essential tremor
05/23/2012CN1938264B Acid addition salts of 5-aminolevulinic acid or its derivatives
05/23/2012CN1906162B Hydroxy piperidine derivatives to treat gaucher disease
05/23/2012CN1726185B Halogenated selective androgen receptor modulators and using method thereof
05/23/2012CN1659288B Pharmaceutical composition for preventing or reducing DNA damage
05/23/2012CN1561340B Novel 1,2,4-triazole compound
05/23/2012CN1492763B Compositions for delivering bisphosphonates
05/23/2012CN102471795A 含有虾青素的组合物的制备方法 Preparation of astaxanthin-containing composition
05/23/2012CN102471770A Antigen peptide and use thereof
05/23/2012CN102471765A Neurotoxins exhibiting shortened biological activity
05/23/2012CN102471366A 17-羟基-17-五氟乙基雌-4,9(10)-二烯11-苯亚甲基衍生物、其制备方法及其用于治疗疾病的用途 17- hydroxy-17-pentafluoroethyl estrogen-4,9 (10) - diene-11- benzylidene derivatives, their preparation and their use for the treatment of diseases
05/23/2012CN102471365A 17-羟基-17-五氟乙基雌-4,9(10)-二烯11-乙炔基苯基衍生物、其制备方法及其在治疗病症中的应用 17- hydroxy-17-pentafluoroethyl estrogen-4,9 (10) - diene 11- ethynylphenyl derivatives, their preparation and their use in the treatment of disorders
05/23/2012CN102471363A Novel flavanone derivative
05/23/2012CN102471362A 用于治疗或预防流行性角膜结膜炎的新型抗病毒化合物 For the treatment or prevention of epidemic keratoconjunctivitis novel antiviral compounds
05/23/2012CN102471361A 作为神经氨酸酶抑制剂的2，3-氟化糖苷及其作为抗病毒药物的用途 As neuraminidase inhibitors 2,3-fluorinated glycoside use as antiviral agents
05/23/2012CN102471355A 二苯硫醚衍生物和含有其作为活性成分的药物 Diphenyl sulfide derivative and a pharmaceutical containing it as an active ingredient
05/23/2012CN102471351A 用作pi3k抑制剂的2-羧酰胺环氨基脲 Used as pi3k inhibitor 2- carboxamide ring semicarbazide
05/23/2012CN102471350A 制造头孢喹肟颗粒的方法 The method of manufacturing Cefquinome particles
05/23/2012CN102471349A 构象受限的完全合成的大环化合物 Completely synthetic macrocyclic compounds conformationally constrained
05/23/2012CN102471347A Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
05/23/2012CN102471346A Jak的三环抑制剂 Jak tricyclic inhibitors
05/23/2012CN102471343A 作为自分泌运动因子抑制剂的杂环化合物 Heterocyclic compounds as inhibitors of autocrine motility factor
05/23/2012CN102471342A 用作PKC-θ抑制剂的4取代的吡唑并吡啶类 As a 4-substituted pyrazolo pyridine inhibitors PKC-θ
05/23/2012CN102471341A Compounds and compositions for the treatment of parasitic diseases
05/23/2012CN102471339A 激酶的吡咯并吡啶抑制剂 Kinase inhibitors pyrrolopyridine
1 ... 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 ... 7860